Vivoryon Therapeutics Overview
- Founded
-
1997
- Status
-
Public
- Employees
-
17
- Stock Symbol
-
VVY
- Investments
-
1
- Share Price
-
$8.34
- (As of Monday Closing)
Vivoryon Therapeutics General Information
Description
Vivoryon Therapeutics NV is a Germany based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products includes PQ912, PQ1565 and PQ-family.
Contact Information
Website
www.vivoryon.com
Formerly Known As
ProBioTec, Probiodrug
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
AMS
Primary Office
- Weinbergweg 22
- 06120 Halle
- Germany
+49 0345 0000000
Vivoryon Therapeutics Timeline
Vivoryon Therapeutics Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.34 | $8.51 | $6.84 - $26.66 | $188M | 22.1M | 59.3K | -$0.74 |
Vivoryon Therapeutics Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2021 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 406,611 | 406,611 | 183,005 | 112,748 |
| Revenue | 12,726 | 12,726 | 0 | 0 |
| EBITDA | (14,253) | (14,253) | (18,657) | (8,624) |
| Net Income | (14,962) | (14,962) | (18,820) | (8,757) |
| Total Assets | 27,762 | 27,762 | 36,593 | 51,372 |
| Total Debt | 254 | 254 | 386 | 455 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Vivoryon Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vivoryon Therapeutics Patents
Vivoryon Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3750878-A1 | Heteroaromatic inhibitors of astacin proteinases | Pending | 14-Jun-2019 | 0000000000 | 0 |
| EP-3409785-A1 | Continuous spectrometric assay for measuring meprin activity using an auxiliary enzyme | Withdrawn | 30-May-2017 | 00000000 | 0 |
| EP-3635128-B1 | Continuous spectrometric assays for measuring meprin activity using an auxiliary enzyme | Active | 30-May-2017 | 00000000 | |
| EP-3635128-A1 | Continuous spectrometric assays for measuring meprin activity using an auxiliary enzyme | Granted | 30-May-2017 | 00000000 | |
| CA-3057783-A1 | Novel inhibitors | Pending | 31-Mar-2017 | A61P25/00 |
Vivoryon Therapeutics Executive Team (14)
Vivoryon Therapeutics Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Erich Platzer Ph.D | Self | Chairman & Board Member | 000 0000 |
| Michael Schaeffer Ph.D | Self | Board Member & Executive | 000 0000 |
| Ulrich Dauer Ph.D | Vivoryon Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
Vivoryon Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Vivoryon Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Vivoryon Therapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 0000 | 25-Jun-2007 | 0000000000 | Pharmaceuticals |